Q-omics provides the consensus-scored CD96 profile across patient tissues and cancer cell-line models. CD96 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CD96 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, CD96 RNA expression shows 20,047 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, KIRC, and LSCC as cancer lineages where CD96 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD96 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD96 survival associations across molecular data types. CD96 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD96 RNA expression–survival associations across cancer types. High CD96 expression shows favorable associations in BLCA, HNSC, SKCM, UCEC, BRCA and CESC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for CD96 RNA expression.
This table summarizes CD96 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CD96. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD96 shows lower tumor expression in COAD, THCA and LUSC and higher tumor expression in KIRC, STAD and KIRP. The KIRC box plot shows higher CD96 RNA expression in tumor versus normal tissue (log2 FC = +2.006, t-test p < 0.001).
This table shows molecular features associated with CD96 in patient tissues and cancer cell lines. In patient samples, CD96 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CD96 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
